Table of Contents

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q

 

(Mark One)

 

x

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended April 4, 2009

 

OR

 

o

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                        to

 

Commission file number: 0-21116

 


 

USANA HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Utah

 

87-0500306

(State or other jurisdiction

 

(I.R.S. Employer

of incorporation or organization)

 

Identification No.)

 


 

3838 West Parkway Blvd., Salt Lake City, Utah 84120

(Address of principal executive offices, Zip Code)

 


 

(801) 954-7100

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x  No o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o  No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.  (Check one):

 

Large accelerated filer o

 

Accelerated filer x

 

 

 

Non-accelerated filer o

 

Smaller reporting company o

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o  No x

 

The number of shares outstanding of the registrant’s common stock as of May 1, 2009 was 15,350,933.

 

 

 



Table of Contents

 

USANA HEALTH SCIENCES, INC.

 

FORM 10-Q

 

For the Quarterly Period Ended April 4, 2009

 

INDEX

 

 

 

Page

 

 

 

 

PART I. FINANCIAL INFORMATION

 

 

 

 

Item 1

Financial Statements (unaudited)

 

 

Consolidated Balance Sheets

3

 

Consolidated Statements of Earnings

4

 

Consolidated Statements of Stockholders’ Equity and Comprehensive Income

5

 

Consolidated Statements of Cash Flows

6

 

Notes to Consolidated Financial Statements

7–16

Item 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

16–23

Item 3

Quantitative and Qualitative Disclosures About Market Risk

23-24

Item 4

Controls and Procedures

25

 

 

 

 

PART II.OTHER INFORMATION

 

 

 

 

Item 6

Exhibits

26-27

 

 

 

Signatures

 

28

 

2



Table of Contents

 

PART I.  FINANCIAL INFORMATION

 

Item 1.  Financial Statements

 

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

 

CONSOLIDATED BALANCE SHEETS

(in thousands)

 

 

 

As of

 

As of

 

 

 

January 3,

 

April 4,

 

 

 

2009 (1)

 

2009

 

 

 

 

 

(unaudited)

 

ASSETS

 

 

 

 

 

Current assets

 

 

 

 

 

Cash and cash equivalents

 

$

13,281

 

$

9,747

 

Inventories

 

23,879

 

27,397

 

Prepaid expenses and other current assets

 

12,657

 

9,525

 

Deferred income taxes

 

2,857

 

2,637

 

Total current assets

 

52,674

 

49,306

 

 

 

 

 

 

 

Property and equipment, net

 

56,762

 

56,359

 

 

 

 

 

 

 

Assets held for sale

 

607

 

607

 

Goodwill

 

5,690

 

5,690

 

Other assets

 

6,839

 

7,794

 

 

 

$

122,572

 

$

119,756

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

Current liabilities

 

 

 

 

 

Accounts payable

 

$

6,879

 

$

7,640

 

Other current liabilities

 

47,655

 

35,848

 

Total current liabilities

 

54,534

 

43,488

 

 

 

 

 

 

 

Line of credit

 

34,990

 

33,900

 

 

 

 

 

 

 

Other long-term liabilities

 

1,212

 

1,618

 

 

 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

Common stock, $0.001 par value;

 

 

 

 

 

Authorized — 50,000 shares, issued and outstanding 15,350 as of January 3, 2009 and 15,350 as of April 4, 2009

 

15

 

15

 

Additional paid-in capital

 

8,089

 

10,603

 

Retained earnings

 

24,107

 

30,753

 

Accumulated other comprehensive income (loss)

 

(375

)

(621

)

Total stockholders’ equity

 

31,836

 

40,750

 

 

 

$

122,572

 

$

119,756

 

 


(1) Derived from audited financial statements.

 

The accompanying notes are an integral part of these statements.

 

3



Table of Contents

 

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

 

CONSOLIDATED STATEMENTS OF EARNINGS

 

(in thousands, except per share data)

 

(unaudited)

 

 

 

Quarter Ended

 

 

 

March 29,

 

April 4,

 

 

 

2008

 

2009

 

 

 

(as restated)

 

 

 

 

 

 

 

 

 

Net sales

 

$

101,570

 

$

97,299

 

 

 

 

 

 

 

Cost of sales

 

21,502

 

19,846

 

 

 

 

 

 

 

Gross profit

 

80,068

 

77,453

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

Associate incentives

 

41,364

 

41,890

 

Selling, general and administrative

 

27,036

 

25,330

 

 

 

 

 

 

 

Total operating expenses

 

68,400

 

67,220

 

 

 

 

 

 

 

Earnings from continuing operations

 

11,668

 

10,233

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

Interest income

 

98

 

18

 

Interest expense

 

(239

)

(289

)

Other, net

 

70

 

181

 

 

 

 

 

 

 

Other expense, net

 

(71

)

(90

)

 

 

 

 

 

 

Earnings from continuing operations before income taxes

 

11,597

 

10,143

 

 

 

 

 

 

 

Income taxes

 

4,304

 

3,497

 

 

 

 

 

 

 

Net earnings

 

7,293

 

6,646

 

 

 

 

 

 

 

Earnings per common share

 

 

 

 

 

Basic

 

 

 

 

 

Net earnings

 

$

0.45

 

$

0.43

 

 

 

 

 

 

 

Diluted

 

 

 

 

 

Net earnings

 

$

0.44

 

$

0.43

 

 

 

 

 

 

 

Weighted average common shares outstanding

 

 

 

 

 

Basic

 

16,363

 

15,350

 

Diluted

 

16,459

 

15,382

 

 

The accompanying notes are an integral part of these statements.

 

4



Table of Contents

 

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

 

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY AND COMPREHENSIVE INCOME

 

Quarters Ended March 29, 2008 and April 4, 2009

 

(in thousands)

 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

Additional

 

 

 

Other

 

 

 

 

 

Common Stock

 

Paid-in

 

Retained

 

Comprehensive

 

 

 

 

 

Shares

 

Value

 

Capital

 

Earnings

 

Income (Loss)

 

Total

 

For the Quarter Ended March 29, 2008

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 29, 2007 (as restated)

 

16,198

 

$

16

 

$

5,636

 

$

26,308

 

$

989

 

$

32,949

 

Comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

Net earnings for the quarter

 

 

 

 

 

 

 

7,293

 

 

 

7,293

 

Foreign currency translation adjustment, net of tax benefit of $200

 

 

 

 

 

 

 

 

 

586

 

586

 

Comprehensive income

 

 

 

 

 

 

 

 

 

 

 

7,879

 

Equity-based compensation expense

 

 

 

 

 

1,488

 

 

 

 

 

1,488

 

Common stock issued under equity award plans, including tax benefit of $1,113

 

194

 

 

 

1,443

 

 

 

 

 

1,443

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at March 29, 2008 (as restated)

 

16,392

 

$

16

 

$

8,567

 

$

33,601

 

$

1,575

 

$

43,759

 

For the Quarter Ended April 4, 2009

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at January 3, 2009

 

15,350

 

15

 

8,089

 

24,107

 

(375

)

31,836

 

Comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

Net earnings for the quarter

 

 

 

 

 

 

 

6,646

 

 

 

6,646

 

Foreign currency translation adjustment, net of tax benefit of $28

 

 

 

 

 

 

 

 

 

(246

)

(246

)

Comprehensive income

 

 

 

 

 

 

 

 

 

 

 

6,400

 

Equity-based compensation expense

 

 

 

 

 

2,514

 

 

 

 

 

2,514

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at April 4, 2009

 

15,350

 

$

15

 

$

10,603

 

$

30,753

 

$

(621

)

$

40,750

 

 

The accompanying notes are an integral part of these statements.

 

5



Table of Contents

 

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

 

 

 

Quarter Ended

 

 

 

March 29,

 

April 4,

 

 

 

2008

 

2009

 

 

 

(as restated)

 

 

 

Cash flows from operating activities

 

 

 

 

 

Net earnings

 

$

7,293

 

$

6,646

 

Adjustments to reconcile net earnings to net cash provided by (used in) operating activities

 

 

 

 

 

Depreciation and amortization

 

1,609

 

1,826

 

(Gain) loss on sale of property and equipment

 

(92

)

20

 

Equity-based compensation expense

 

1,488

 

2,514

 

Excess tax benefit from equity-based payment arrangements

 

(1,113

)

 

Deferred income taxes

 

(927

)

(742

)

Provision for inventory valuation

 

200

 

300

 

Changes in operating assets and liabilities:

 

 

 

 

 

Inventories

 

(1,571

)

(3,870

)

Prepaid expenses and other assets

 

2,270

 

2,873

 

Accounts payable

 

609

 

780

 

Other liabilities

 

(706

)

(11,621

)

 

 

 

 

 

 

Total adjustments

 

1,767

 

(7,920

)

 

 

 

 

 

 

Net cash provided by (used in) operating activities

 

9,060

 

(1,274

)

 

 

 

 

 

 

Cash flows from investing activities

 

 

 

 

 

Receipts on notes receivable

 

$

37

 

$

64

 

Increase in notes receivable

 

(8

)

 

Proceeds from sale of property and equipment

 

122

 

 

Purchases of property and equipment

 

(6,080

)

(953

)

 

 

 

 

 

 

Net cash used in investing activities

 

(5,929

)

(889

)

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

Proceeds from equity awards exercised

 

$

330

 

$

 

Excess tax benefits from equity-based payment arrangements

 

1,113

 

 

Borrowings on line of credit

 

 

27,550

 

Payments on line of credit

 

 

(28,640

)

 

 

 

 

 

 

Net cash provided by (used in) financing activities

 

1,443

 

(1,090

)

 

 

 

 

 

 

Effect of exchange rate changes on cash and cash equivalents

 

127

 

(281

)

 

 

 

 

 

 

Net increase (decrease) in cash and cash equivalents

 

4,701

 

(3,534

)

 

 

 

 

 

 

Cash and cash equivalents, beginning of year

 

12,865

 

13,281

 

 

 

 

 

 

 

Cash and cash equivalents, end of year

 

$

17,566

 

$

9,747

 

 

 

 

 

 

 

Supplemental disclosures of cash flow information

 

 

 

 

 

 

 

 

 

 

 

Cash paid during the period for:

 

 

 

 

 

Interest, net of amount capitalized

 

$

178

 

$

278

 

Income taxes

 

1,416

 

316

 

 

The accompanying notes are an integral part of these statements.

 

6



Table of Contents

 

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

 

Basis of Presentation

 

The unaudited interim consolidated financial information of USANA Health Sciences, Inc. and its subsidiaries (collectively, the “Company” or “USANA”) has been prepared in accordance with Article 10 of Regulation S-X promulgated by the Securities and Exchange Commission.  Certain information and footnote disclosures that are normally included in financial statements that have been prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations.  In the opinion of management, the accompanying interim consolidated financial information contains all adjustments, consisting of normal recurring adjustments that are necessary to present fairly the Company’s financial position as of April 4, 2009, and results of operations for the quarters ended March 29, 2008 and April 4, 2009.  These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto that are included in the Company’s Annual Report on Form 10-K for the year ended January 3, 2009.  The results of operations for the quarter ended April 4, 2009 may not be indicative of the results that may be expected for the fiscal year 2009 ending January 2, 2010.

 

Recently Adopted Accounting Pronouncements

 

In March 2008, the FASB issued SFAS No. 161, “Disclosures about Derivative Instruments and Hedging Activities—an amendment of SFAS No. 133.”  This Standard requires enhanced disclosures regarding derivatives and hedging activities, including: (a) the manner in which an entity uses derivative instruments; (b) the manner in which derivative instruments and related hedged items are accounted for under SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities; and (c) the effect of derivative instruments and related hedged items on an entity’s financial position, financial performance, and cash flows. The Standard is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008.  The Company adopted SFAS 161 on January 4, 2009.  The adoption had no financial impact on the Company’s consolidated financial statements and only required additional financial statement disclosures.  The Company has applied the requirements of SFAS 161 on a prospective basis.  Accordingly, disclosures related to interim and annual periods prior to the date of adoption will not be presented.

 

In December 2007, the FASB issued SFAS No. 141 (revised 2007), “Business Combinations”, or SFAS 141R, which replaces SFAS 141, “Business Combinations”.  SFAS 141R establishes principles and requirements for how an acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, any non-controlling interest and the goodwill acquired.  SFAS 141R also modifies the recognition for pre-acquisition contingencies, such as environmental or legal issues, restructuring plans and acquired research and development value in purchase accounting.  SFAS 141R amends SFAS No. 109, “Accounting for Income Taxes”, to require the acquirer to recognize changes in the amount of its deferred tax benefits that are recognizable because of a business combination either in income from continuing operations in the period of the combination or directly in contributed capital, depending on the circumstances.  SFAS 141R also establishes disclosure requirements which will enable users to evaluate the nature and financial effects of the business combination.  SFAS 141R is effective for fiscal years beginning after December 15, 2008.  The Company adopted SFAS 141R on January 4, 2009 and the adoption did not have a material impact on its consolidated financial statements.

 

7



Table of Contents

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (continued)

(in thousands, except per share data)

(unaudited)

 

Restatement of consolidated financial statements

 

In its Annual Report on Form 10-K filed with the SEC on March 6, 2009, the Company restated its historical consolidated financial statements for the fiscal years ending December 29, 2007 and December 30, 2006 to correct two errors related to income taxes payable during the reported periods, as explained below.

 

During 2008, the Internal Revenue Service (“IRS”) commenced an audit of the Company’s tax returns. In January 2009, the IRS communicated its intent to disallow deductions claimed by the Company under Section 162(m) of the Internal Revenue Code (“IRC”). In February 2009, the Company settled the Section 162(m) matter with the IRS. Under the settlement, the cumulative tax impact to the Company is the loss of $11.8 million in tax deductions resulting in estimated taxes due of $4.4 million, plus $0.8 million in interest. The $4.4 million in taxes due resulted in an increase to current liabilities and corresponding reduction in stockholders’ equity in the affected periods. The $0.8 million in interest resulted in an increase to current liabilities with a corresponding increase to income tax expense in the affected periods.

 

The IRS also disallowed the treatment of certain stock options granted by the Company as Incentive Stock Options. The Company’s February 2009 settlement with the IRS also settled this matter. The settlement resulted in a cumulative increase of $1.3 million to compensation expense recorded in selling, general and administrative expense for the affected periods.

 

The Company concluded that the cumulative effect of the balance sheet adjustments due to these two errors was material to its fiscal year 2007, as well as its 2007 and 2008 quarterly, balance sheets.  The consolidated financial statements and related disclosures for the quarter ended March 29, 2008 have been restated in this report to reflect the errors discussed above.  The impact of this restatement on the first quarter of 2008 was an increase in selling, general and administrative expense of $289, a decrease to income taxes of $35, a decrease in basic earnings per share of $0.01, a decrease in diluted earnings per share of $0.02, an increase in other current liabilities of $5,943, a decrease in additional paid-in capital of $1,889, and a decrease in retained earnings of $4,054.  Refer to Note A of the 2008 Form 10-K for the effects of the restatement on the Company’s consolidated financial statements as of and for the fiscal years ended December 29, 2007 and January 3, 2009.

 

NOTE A — ORGANIZATION

 

USANA develops and manufactures high-quality nutritional and personal care products that are sold internationally through a network marketing system, which is a form of direct selling.  The Company’s products are sold throughout the United States, Canada, Mexico, Australia, New Zealand, Singapore, Malaysia, the Philippines, Hong Kong, Taiwan, Japan, South Korea, the United Kingdom, and the Netherlands.

 

NOTE B — INVENTORIES

 

Inventories consist of the following:

 

 

 

January 3,

 

April 4,

 

 

 

2009

 

2009

 

 

 

 

 

 

 

Raw materials

 

$

7,063

 

$

7,231

 

Work in progress

 

5,412

 

5,729

 

Finished goods

 

11,404

 

14,437

 

 

 

 

 

 

 

 

 

$

23,879

 

$

27,397

 

 

8



Table of Contents

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (continued)

(in thousands, except per share data)

(unaudited)

 

NOTE C — PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

Prepaid expenses and other current assets consist of the following:

 

 

 

January 3,

 

April 4,

 

 

 

2009

 

2009

 

 

 

 

 

 

 

Prepaid insurance

 

$

1,393

 

$

1,046

 

Other prepaid expenses

 

1,458

 

1,779

 

Federal income taxes receivable

 

3,759

 

1,634

 

Miscellaneous receivables, net

 

3,182

 

2,493

 

Deferred commissions

 

2,174

 

1,899

 

Other current assets

 

691

 

674

 

 

 

 

 

 

 

 

 

$

12,657

 

$

9,525

 

 

NOTE D — PROPERTY AND EQUIPMENT

 

 

 

 

 

January 3,

 

April 4,

 

 

 

Years

 

2009

 

2009

 

 

 

 

 

 

 

 

 

Buildings

 

40

 

$

35,714

 

$

35,819

 

Laboratory and production equipment

 

5-7

 

14,414

 

14,304

 

Sound and video library

 

5

 

600

 

600

 

Computer equipment and software

 

3-5

 

24,626

 

25,861

 

Furniture and fixtures

 

3-5

 

4,474

 

4,403

 

Automobiles

 

3-5

 

201

 

229

 

Leasehold improvements

 

3-5

 

3,871

 

4,208

 

Land improvements

 

15

 

1,979

 

1,988

 

 

 

 

 

 

 

 

 

 

 

 

 

85,879

 

87,412

 

 

 

 

 

 

 

 

 

Less accumulated depreciation and amortization

 

 

 

36,796

 

38,174

 

 

 

 

 

 

 

 

 

 

 

 

 

49,083

 

49,238

 

 

 

 

 

 

 

 

 

Land

 

 

 

6,224

 

6,263

 

 

 

 

 

 

 

 

 

Deposits and projects in process

 

 

 

1,455

 

858

 

 

 

 

 

 

 

 

 

 

 

 

 

$

56,762

 

$

56,359

 

 

9



Table of Contents

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (continued)

(in thousands, except per share data)

(unaudited)

 

NOTE E — OTHER CURRENT LIABILITIES

 

Other current liabilities consist of the following:

 

 

 

January 3,

 

April 4,

 

 

 

2009

 

2009

 

 

 

 

 

 

 

Associate incentives

 

$

6,498

 

$

6,848

 

Accrued employee compensation

 

11,212

 

5,133

 

Income taxes

 

6,243

 

7,575

 

Sales taxes

 

3,923

 

3,151

 

Associate promotions

 

607

 

1,205

 

Deferred revenue

 

6,588

 

5,859

 

Provision for returns and allowances

 

1,101

 

989

 

Arbitration award

 

7,020

 

 

All other

 

4,463

 

5,088

 

 

 

 

 

 

 

 

 

$

47,655

 

$

35,848

 

 

NOTE F — LONG TERM DEBT AND LINE OF CREDIT

 

The Company has a $40,000 line of credit.  At April 4, 2009, there was an outstanding balance of $33,900 associated with the line of credit, with a weighted-average interest rate of 1.56%.  The interest rate is computed at the bank’s Prime Rate or LIBOR, adjusted by features specified in the Credit Agreement.  The collateral for this line of credit is the pledge of the capital stock of certain subsidiaries of the Company, as set forth in a separate pledge agreement with the bank.  The Credit Agreement contains restrictive covenants based on a minimum EBITDA requirement and a debt coverage ratio.  The Company will be required to pay the balance on this line of credit in full at the time of maturity in May 2011.

 

NOTE G — EQUITY-BASED COMPENSATION

 

Equity-based compensation expense relating to equity awards under the current and previous plans of the Company, together with the related tax benefit recognized in earnings for the periods ended as of the dates indicated is as follows:

 

 

 

Quarter Ended

 

 

 

March 29,

 

April 4,

 

 

 

2008

 

2009

 

 

 

 

 

 

 

Cost of sales

 

$

181

 

$

190

 

Selling, general and administrative

 

1,307

 

2,324

 

 

 

 

 

 

 

 

 

1,488

 

2,514

 

Related tax benefit

 

569

 

889

 

 

 

 

 

 

 

Net equity-based compensation expense

 

$

919

 

$

1,625

 

 

10



Table of Contents

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (continued)

(in thousands, except per share data)

(unaudited)

 

NOTE G — EQUITY-BASED COMPENSATION — CONTINUED

 

The following table shows the remaining unrecognized compensation expense on a pre-tax basis for all types of equity awards that were outstanding as of April 4, 2009.  This table does not include an estimate for future grants that may be issued.

 

Remainder of 2009

 

$

6,472

 

2010

 

8,205

 

2011

 

6,788

 

2012

 

5,375

 

2013

 

2,603

 

2014

 

15

 

 

 

$

29,458

 

 

The cost above is expected to be recognized over a weighted-average period of 2.4 years.

 

The Company recognizes equity-based compensation expense under the straight-line method over the vesting term based on the grant date fair value and an estimate of forfeitures derived from historical experience.  The Company uses the Black-Scholes option pricing model to estimate the fair value of its equity awards, which requires the input of highly subjective assumptions, including expected stock price volatility.  Expected volatility is calculated as a weighted-average of historical volatility and implied volatility of the Company.  Risk-free interest rate is based on the U.S. Treasury yield curve on the date of grant with respect to the expected life of the award.  Expected life is calculated as a weighted-average that includes historical settlement data of the Company’s equity awards and a hypothetical holding period for outstanding awards.

 

The following table includes weighted-average assumptions that the Company has used to calculate the fair value of equity awards that were granted during the periods indicated.  Deferred stock units are full-value shares at the date of grant and have been excluded from the table below:

 

 

 

Quarter Ended

 

 

 

March 29,

 

April 4,

 

 

 

2008

 

2009

 

 

 

 

 

 

 

Expected volatility

 

*

 

37.3

%

Risk-free interest rate

 

*

 

1.8

%

Expected life

 

*

 

4.0 yrs.

 

Expected dividend yield

 

*

 

 

Weighted-average grant price

 

*

 

$

26.39

 

 


* There were no equity awards granted during the quarter ended March 29, 2008.

 

11



Table of Contents

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (continued)

(in thousands, except per share data)

(unaudited)

 

NOTE G — EQUITY-BASED COMPENSATION — CONTINUED

 

A summary of the Company’s stock option and stock-settled stock appreciation right activity for the quarter ended April 4, 2009 is as follows:

 

 

 

Shares

 

Weighted-
average grant
price

 

Weighted-average
remaining
contractual term

 

Aggregate
intrinsic
value*

 

Outstanding at January 3, 2009

 

4,244

 

$

30.28

 

4.7

 

$

21,382

 

Granted

 

75

 

26.39

 

 

 

 

 

Exercised

 

 

 

 

 

 

 

Canceled or expired

 

 

 

 

 

 

 

Outstanding at April 4, 2009

 

4,319

 

$

30.21

 

4.5

 

$

726

 

Exercisable at April 4, 2009

 

1,031

 

$

33.98

 

4.4

 

$

726

 

 


*

 

Aggregate intrinsic value is defined as the difference between the current market value at the reporting date and the exercise price of awards that were in-the-money. It is estimated using the closing price of the Company’s common stock on the last trading day of the period reported.

 

There were no stock options or stock-settled stock appreciation rights that were granted during the quarter ended March 29, 2008.  The weighted-average fair value of those that were granted during the quarter ended April 4, 2009 was $8.29.  The total intrinsic value of awards that were exercised during the quarter ended March 29, 2008 was $6,577.  There were no awards exercised during the quarter ended April 4, 2009.

 

The total fair value of awards that vested during the quarters ended March 29, 2008 and April 4, 2009 was $2,885 and $3,763, respectively.  This total fair value includes equity awards that were issued in the form of stock options, stock-settled stock appreciation rights, and deferred stock units.

 

NOTE H — DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

 

The Company designates certain derivatives, such as certain currency option and forward contracts, as freestanding derivatives for which hedge accounting does not apply.  The changes in the fair market value of the derivatives are included in “Other, net” in the Company’s consolidated statements of earnings.  The fair value of any option or forward contract is based on period-end quoted market prices.  The Company does not use derivative financial instruments for trading or speculative purposes.  The use of currency exchange contracts includes the purchase of put and call options, which give the Company the right, but not the obligation, to sell or buy international currency at a specified exchange rate (“strike price”).  In addition, the Company has used forward contracts to supplement its use of options.  The Company’s objective in using currency exchange contracts has been to reduce the impact of currency fluctuations on cash that it repatriates.  The Company is also currently evaluating the costs and benefits of managing currency impacts on net sales and certain balance sheet items.  The Company did not enter into any currency exchange contracts during the quarter ended April 4, 2009.  Furthermore, the exercise of currency contracts that were previously outstanding did not have a material impact on the Company’s consolidated statements of earnings.

 

12



Table of Contents

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (continued)

(in thousands, except per share data)

(unaudited)

 

NOTE I — COMMON STOCK AND EARNINGS PER SHARE

 

Basic earnings per share are based on the weighted-average number of shares outstanding for each period.  Shares that have been repurchased and retired during the periods specified below have been included in the calculation of the number of weighted-average shares that are outstanding for the calculation of basic earnings per share.  Diluted earnings per common share are based on shares that are outstanding (computed under basic EPS) and on potentially dilutive shares.  Shares that are included in the diluted earnings per share calculations include equity awards that are in-the-money but have not yet been exercised.

 

 

 

For the Quarter Ended

 

 

 

March 29,

 

April 4,

 

 

 

2008

 

2009

 

 

 

(as restated)

 

 

 

 

 

 

 

 

 

Net earnings available to common shareholders

 

$

7,293

 

$

6,646

 

 

Basic EPS

 

 

 

 

 

 

 

 

 

 

 

Shares

 

 

 

 

 

Common shares outstanding - entire period

 

 

 

 

 

Weighted-average common shares:

 

16,198

 

15,350

 

Issued during period

 

165

 

 

Canceled during period

 

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding during period

 

16,363

 

15,350

 

 

 

 

 

 

 

Earnings per common share from net earnings - basic

 

$

0.45

 

$

0.43

 

 

Diluted EPS

 

 

 

 

 

 

 

 

 

 

 

Shares

 

 

 

 

 

Weighted-average shares outstanding during period - basic

 

16,363

 

15,350

 

Dilutive effect of equity awards

 

96

 

32

 

 

 

 

 

 

 

Weighted-average shares outstanding during period - diluted

 

16,459

 

15,382

 

 

 

 

 

 

 

Earnings per common share from net earnings - diluted

 

$

0.44

 

$

0.43

 

 

Equity awards for 1,261 and 4,286 shares of stock were not included in the computation of diluted EPS for the quarters ended March 29, 2008, and April 4, 2009, respectively, due to the fact that their exercise prices were greater than the average market price of the shares.

 

13



Table of Contents

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (continued)

(in thousands, except per share data)

(unaudited)

 

NOTE J — SEGMENT INFORMATION

 

USANA operates as a direct selling company that develops, manufactures, and distributes high-quality nutritional and personal care products that are sold through a global network marketing system of independent distributors (“Associates”).  The table below summarizes the approximate percentage of total product revenue that has been contributed by the Company’s nutritional and personal care products for the periods indicated.

 

 

 

Quarter Ended

 

 

 

March 29,

 

April 4,

 

Product Line

 

2008

 

2009

 

USANAÒ Nutritionals

 

88

%

88

%

Sensé — beautiful scienceÒ

 

10

%

9

%

 

The Company’s primary business is to manage its worldwide Associate base.  As such, management has determined that the Company operates in one reportable business segment as defined in SFAS No. 131, “Disclosures about Segments of an Enterprise and Related Information.”  Performance for a region or market is primarily evaluated based on sales.  The Company does not use profitability reports on a regional or market basis for making business decisions.  No single customer accounted for 10% or more of net sales for the periods presented.

 

Selected financial information for the Company is presented for two geographic regions: North America and Asia Pacific, with three sub-regions under Asia Pacific.  Individual markets are categorized into these regions as follows:

 

·                  North America

 

·                  United States

 

·                  Canada

 

·                  Mexico

 

·                  Asia Pacific

 

·                  Southeast Asia/Pacific* — Australia, New Zealand, Singapore, Malaysia, and Philippines

 

·                  East Asia — Hong Kong and Taiwan

 

·                  North Asia — Japan and South Korea

 


*Operations in the Philippines commenced in January 2009.

 

14



Table of Contents

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (continued)

(in thousands, except per share data)

(unaudited)

 

NOTE J — SEGMENT INFORMATION — CONTINUED

 

Selected Financial Information

 

Selected financial information, presented by geographic region, is listed below for the periods ended as of the dates indicated:

 

 

 

Quarter ended

 

 

 

March 29,

 

April 4,

 

 

 

2008

 

2009

 

Net Sales to External Customers

 

 

 

 

 

North America

 

 

 

 

 

United States

 

$

38,550

 

$

36,489

 

Canada

 

18,583

 

14,936

 

Mexico

 

5,142

 

4,470

 

North America Total

 

62,275

 

55,895

 

Asia Pacific

 

 

 

 

 

Southeast Asia/Pacific

 

21,545

 

19,938

 

East Asia

 

13,615

 

16,955

 

North Asia

 

4,135

 

4,511

 

Asia Pacific Total

 

39,295

 

41,404

 

 

 

 

 

 

 

Consolidated Total

 

$

101,570

 

$

97,299

 

 

 

 

 

 

 

Total Assets

 

 

 

 

 

North America

 

 

 

 

 

United States

 

$

77,219

 

$

80,008

 

Canada

 

4,642

 

2,230

 

Mexico

 

4,272

 

3,359

 

North America Total

 

86,133

 

85,597

 

Asia Pacific

 

 

 

 

 

Southeast Asia/Pacific

 

20,210

 

22,280

 

East Asia

 

7,197

 

8,322

 

North Asia

 

4,476

 

3,557

 

Asia Pacific Total

 

31,883

 

34,159

 

 

 

 

 

 

 

Consolidated Total

 

$

118,016

 

$

119,756

 

 

The following table provides further information on markets representing ten percent or more of consolidated net sales:

 

 

 

Quarter ended

 

 

 

March 29,

 

April 4,

 

 

 

2008

 

2009

 

Net Sales:

 

 

 

 

 

United States

 

$

38,550

 

$

36,489

 

Canada

 

18,583

 

14,936

 

Hong Kong

 

8,381

 

11,901

 

 

15



Table of Contents

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (continued)

(in thousands, except per share data)

(unaudited)

 

NOTE J — SEGMENT INFORMATION — CONTINUED

 

Due to the centralized structure of the Company’s manufacturing operations and its corporate headquarters in the United States, a significant concentration of assets exists in this market.  As of March 29, 2008, and April 4, 2009, long-lived assets in the United States totaled $48,687 and $48,312, respectively.  Additionally, long-lived assets in the Australia market as of March 29, 2008, and April 4, 2009 totaled $10,799 and $11,489, respectively.  There is no significant concentration of long-lived assets in any other market.

 

Item 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of USANA’s financial condition and results of operations should be read in conjunction with the Unaudited Consolidated Financial Statements and Notes thereto that are contained in this quarterly report, as well as Management’s Discussion and Analysis of Financial Condition and Results of Operations that are included in our Annual Report on Form 10-K for the year ended January 3, 2009, and our other filings, including Current Reports on Form 8-K, that have been filed with the Securities and Exchange Commission (“SEC”) through the date of this report.

 

Our fiscal year end is the Saturday closest to December 31st of each year.  Fiscal year 2009 will end on January 2, 2010 and is a 52-week year.  Fiscal year 2008 ended on January 3, 2009 and was a 53-week year.

 

Overview

 

We develop and manufacture high-quality nutritional and personal care products that are distributed internationally through a network marketing system, which is a form of direct selling.  Our customer base comprises two types of customers; “Associates” and “Preferred Customers.”  Associates are independent distributors of our products who also purchase our products for their personal use.  Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products.  As of April 4, 2009, we had approximately 184,000 active Associates and approximately 68,000 active Preferred Customers worldwide.  For purposes of this report, we only count as active customers those Associates and Preferred Customers who have purchased product from USANA at any time during the most recent three-month period, either for personal use or for resale.

 

We have ongoing operations in the following markets, which are grouped and presented as follows:

 

·                  North America

 

·                  United States

 

·                  Canada

 

·                  Mexico

 

·                  Asia Pacific

 

·                  Southeast Asia/Pacific — Australia, New Zealand, Singapore, Malaysia, and the Philippines*

 

·                  East Asia — Hong Kong and Taiwan

 

·                  North Asia — Japan and South Korea

 


*Operations in the Philippines commenced in January 2009.

 

16



Table of Contents

 

Because we have operations in multiple markets, with sales and expenses being generated and incurred in multiple currencies, our reported sales and earnings can be significantly affected by fluctuations in currency exchange rates.  In general, our reported sales and earnings are affected positively by a weakening of the U.S. dollar and negatively by a strengthening of the U.S. dollar.

 

Our primary product lines consist of USANAâ Nutritionals and Sensé – beautiful scienceâ (Sensé), which is our line of personal care products.  The USANA Nutritionals product line is further categorized into three separate classifications: Essentials, Optimizers, and Macro Optimizers.  The following tables summarize the approximate percentage of total product revenue that has been contributed by our major product lines and our top-selling products for the current and prior-year periods indicated:

 

 

 

Quarter Ended

 

 

 

March 29,

 

April 4,

 

Product Line

 

2008

 

2009

 

USANAâ Nutritionals

 

 

 

 

 

Essentials

 

35

%

33

%

Optimizers

 

40

%

43

%

Macro Optimizers

 

13

%

12

%

Sensé – beautiful scienceâ

 

10

%

9

%

All Other *

 

2

%

3

%

 

 

 

 

 

 

 


* Includes items such as resource materials and services, sales tools, and logo merchandise.

 

 

 

Quarter Ended

 

 

 

March 29,

 

April 4,

 

Key Product

 

2008

 

2009

 

USANAâ Essentials

 

20

%

19

%

HealthPak 100 ™

 

12

%

12

%

Proflavanolâ

 

10

%

11

%

 

As a manufacturer of nutritional and personal care products utilizing direct selling for the distribution of our products, we compete within two industries: direct selling and nutrition.  We believe that the most significant factors affecting us are the aging of the worldwide population, the general public’s heightened awareness and understanding of the connection between diet and health, and the growing desire for a secondary source of income, all of which affect our ability to attract and retain Associates and Preferred Customers to sell and consume our products.

 

The number of active Associates and Preferred Customers is used by management as a key non-financial measure because the number of customers purchasing our products is a leading indicator for product sales.  Associate sales account for the majority of our product sales, representing 89% of product sales during the first quarter of 2009.  During the periods presented, changes in product sales were not significantly affected by changes in product price, rather, they were affected by variations in sales volumes principally relating to changes in the number of active Associates and Preferred Customers purchasing our products.  Notably, the volume of average monthly product purchases by our active Associates and Preferred Customers, in their local currencies, has remained relatively constant over time.  Accordingly, sales growth in local currencies is driven primarily by an increased number of active Associates and also Preferred Customers, rather than through increases in product purchase productivity.

 

We believe that our high-quality products and our financially rewarding Associate compensation plan (“Compensation Plan”) are the key components to attracting and retaining Associates.  To support our Associates in building their businesses, we sponsor meetings and events throughout the year, which offer information about our products and our network marketing system.  These meetings are designed to assist Associates in their business development and to provide a forum for interaction with some of our Associate leaders and members of the USANA management team.  We also provide low cost sales tools, which we believe are an integral part of building and maintaining a successful home-based business for our Associates.

 

17



Table of Contents

 

In addition to Company-sponsored meetings and sales tools, we maintain a website exclusively for our Associates where they can keep up-to-date on the latest USANA news, obtain training materials, manage their personal information, enroll new customers, shop, and register for Company-sponsored events.  Additionally, through this website, Associates can access other online services to which they may subscribe.  For example, we offer an online business management service, which includes a tool that helps Associates track and manage their business activity, a personal webpage to which their prospects or retail customers can be directed, e-cards for advertising, and a tax management tool.

 

The tables below summarize the changes in our active customer base by geographic region.  These numbers have been rounded to the nearest thousand as of the dates indicated.

 

 

 

Active Associates By Region

 

 

 

 

 

 

 

As of

 

As of

 

Change from

 

Percent

 

 

 

March 29, 2008

 

April 4, 2009

 

Prior Year

 

Change

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

North America:

 

 

 

 

 

 

 

 

 

 

 

 

 

United States

 

58,000

 

35.4

%

58,000

 

31.5

%

 

0.0

%

Canada

 

25,000

 

15.2

%

26,000

 

14.1

%

1,000

 

4.0

%

Mexico

 

12,000

 

7.3

%

13,000

 

7.1

%

1,000

 

8.3

%

North America Total

 

95,000

 

57.9

%

97,000

 

52.7

%

2,000

 

2.1

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Asia Pacific:

 

 

 

 

 

 

 

 

 

 

 

 

 

Southeast Asia/Pacific

 

37,000

 

22.6

%

45,000

 

24.5

%

8,000

 

21.6

%

East Asia

 

26,000

 

15.8

%

35,000

 

19.0

%

9,000

 

34.6

%

North Asia

 

6,000

 

3.7

%

7,000

 

3.8

%

1,000

 

16.7

%

Asia Pacific Total

 

69,000

 

42.1

%

87,000

 

47.3

%

18,000

 

26.1

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

164,000

 

100.0

%

184,000

 

100.0

%

20,000

 

12.2

%

 

 

 

Active Preferred Customers By Region

 

 

 

 

 

 

 

As of

 

As of

 

Change from

 

Percent

 

 

 

March 29, 2008

 

April 4, 2009

 

Prior Year

 

Change

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

North America:

 

 

 

 

 

 

 

 

 

 

 

 

 

United States

 

49,000

 

63.6

%

41,000

 

60.3

%

(8,000

)

(16.3

)%

Canada

 

18,000

 

23.4

%

16,000

 

23.6

%

(2,000

)

(11.1

)%

Mexico

 

2,000

 

2.6

%

3,000

 

4.4

%

1,000

 

50.0

%

North America Total

 

69,000

 

89.6

%

60,000

 

88.3

%

(9,000

)

(13.0

)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Asia Pacific:

 

 

 

 

 

 

 

 

 

 

 

 

 

Southeast Asia/Pacific

 

6,000

 

7.8

%

7,000

 

10.3

%

1,000

 

16.7

%

East Asia

 

1,000

 

1.3

%

1,000

 

1.4

%

 

0.0

%

North Asia

 

1,000

 

1.3

%

**

 

0.0

%

(1,000

)

(100.0

)%

Asia Pacific Total

 

8,000

 

10.4

%

8,000

 

11.7

%

 

0.0

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

77,000

 

100.0

%

68,000

 

100.0

%

(9,000

)

(11.7

)%

 


** Active Preferred Customer count is less than 500.

 

18



Table of Contents

 

 

 

Total Active Customers By Region

 

 

 

 

 

 

 

As of

 

As of

 

Change from

 

Percent

 

 

 

March 29, 2008

 

April 4, 2009

 

Prior Year

 

Change

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

North America:

 

 

 

 

 

 

 

 

 

 

 

 

 

United States

 

107,000

 

44.4

%

99,000

 

39.3

%

(8,000

)

(7.5

)%

Canada

 

43,000

 

17.9

%

42,000

 

16.7

%

(1,000

)

(2.3

)%

Mexico

 

14,000

 

5.8

%

16,000

 

6.3

%

2,000

 

14.3

%

North America Total

 

164,000

 

68.1

%

157,000

 

62.3

%

(7,000

)

(4.3

)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Asia Pacific:

 

 

 

 

 

 

 

 

 

 

 

 

 

Southeast Asia/Pacific

 

43,000

 

17.8

%

52,000

 

20.6

%

9,000

 

20.9

%

East Asia

 

27,000

 

11.2

%

36,000

 

14.3

%

9,000

 

33.3

%

North Asia

 

7,000

 

2.9

%

7,000

 

2.8

%

 

0.0

%

Asia Pacific Total

 

77,000

 

31.9

%

95,000

 

37.7

%

18,000

 

23.4

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

241,000

 

100.0

%

252,000

 

100.0

%

11,000

 

4.6

%

 

Our primary growth strategy includes continuing to attract and retain Associates through increased investment in Associate events and the marketing of our Compensation Plan.  This includes continued Associate education on our Compensation Plan and the two enhancements that were announced during the third quarter of 2008.  Some of the other growth opportunities that we frequently evaluate are entering new markets, introducing new and re-formulating existing products, strategic acquisitions, and capital investments that will help support our growth.

 

Forward-Looking Statements and Certain Risks

 

The statements contained in this report that are not purely historical are considered to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act.  These statements represent our expectations, hopes, beliefs, anticipations, commitments, intentions, and strategies regarding the future.  They may be identified by the use of words or phrases such as “believes,” “expects,” “anticipates,” “should,” “plans,” “estimates,” and “potential,” among others.  Forward-looking statements include, but are not limited to, statements contained in Management’s Discussion and Analysis of Financial Condition and Results of Operations regarding our financial performance, revenue, and expense levels in the future and the sufficiency of our existing assets to fund our future operations and capital spending needs.  Readers are cautioned that actual results could differ materially from the anticipated results or other expectations that are expressed in these forward-looking statements for the reasons that are detailed in our most recent Annual Report on Form 10-K.  The fact that some of these risk factors may be the same or similar to those in our past SEC reports means only that the risks are present in multiple periods.  We believe that many of the risks detailed here and in our other SEC filings are part of doing business in the industry in which we operate and will likely be present in all periods reported.  The fact that certain risks are common in the industry does not lessen their significance.  The forward-looking statements contained in this report, are made as of the date of this report, and we assume no obligation to update them or to update the reasons why our actual results could differ from those that we have projected.  Among others, risks and uncertainties that may affect our business, financial condition, performance, development, and results of operations include:

 

·                  Our ability to attract and maintain a sufficient number of Associates;

 

·                  Our dependence upon a network marketing system to distribute our products;

 

·                  Activities of our independent Associates;

 

·                  Our planned expansion into international markets, including delays in commencement of sales in any new market, delays in compliance with local marketing or other regulatory requirements, or changes in target markets;

 

19



Table of Contents

 

·                  Rigorous government scrutiny of network marketing practices;

 

·                  Potential political events, natural disasters, or other events that may negatively affect economic conditions;

 

·                  Potential effects of adverse publicity regarding the Company, nutritional supplements, or the network marketing industry;

 

·                  Reliance on key management personnel;

 

·                  Extensive government regulation of the Company’s products, manufacturing, and network marketing system;

 

·                  Potential inability to sustain or manage growth, including the failure to continue to develop new products;

 

·                  An increase in the amount of Associate incentives;

 

·                  Our reliance on the use of information technology;

 

·                  The adverse effect of the loss of a high-level sponsoring Associate, together with a group of leading Associates, in that person’s downline;

 

·                  The loss of product market share or Associates to competitors;

 

·                  Potential adverse effects of customs, duties, taxation, and transfer pricing regulations, including regulations governing distinctions between and Company responsibilities to employees and independent contractors;

 

·                  The fluctuation in the value of foreign currencies against the U.S. dollar;

 

·                  Our reliance on outside suppliers for raw materials and certain manufactured items;

 

·                  Shortages of raw materials that we use in certain of our products;

 

·                  Significant price increases of our key raw materials;

 

·                  Product liability claims and other risks that may arise with our manufacturing activity;

 

·                  Intellectual property risks;

 

·                  Liability claims that may arise with our “Athlete Guarantee” program;

 

·                  Continued compliance with debt covenants;

 

·                  Disruptions to shipping channels that are used to distribute our products to international warehouses; and

 

·                  The outcome of regulatory and litigation matters.

 

Results of Operations
 
Summary of Financial Results and Recent Developments
 

Net sales for the first quarter of 2009 were $97.3 million compared with $101.6 million in the first quarter of 2008.  This decrease was primarily due to negative changes in currency exchange rates (i.e. a significant strengthening of the U.S. dollar), which reduced net sales by approximately $10.4 million, and was also due to a $2.0 million decrease in sales in the United States.  Excluding the impact of negative changes in currency exchange rates, sales in most of our markets increased from the first quarter of 2008 to the first quarter of 2009.  Additionally, we commenced operations in the Philippines in January, which added $1.7 million to net sales for the quarter.

 

20



Table of Contents

 

The total number of active Associates in the first quarter of 2009 increased 12.2% from the first quarter of 2008.  We believe this increase is due to the enhancements to our Compensation Plan that we implemented during 2008.  The number of Preferred Customers decreased 11.7% from the first quarter of 2008.  We believe that the deteriorating global economic conditions have contributed significantly to the decline in the number of Preferred Customers.

 

Net earnings decreased 8.9% to $6.6 million in the first quarter of 2009 from $7.3 million in the first quarter of 2008.  This decrease was due primarily to lower net sales resulting from negative changes to currency exchange rates, declining sales in the United States, and higher Associate incentives expense.  These were offset in part by lower selling, general and administrative expense and a lower effective tax rate.

 

Quarters Ended March 29, 2008 and April 4, 2009

 

Net Sales

 

The following table summarizes the changes in our net sales by geographic region for the quarters ended as of the dates indicated:

 

 

 

Net Sales by Region

 

 

 

 

 

 

 

Change

 

 

 

(in thousands)

 

Change

 

 

 

Impact of

 

excluding

 

 

 

Quarter Ended

 

from prior

 

Percent

 

currency

 

the impact

 

 

 

March 29, 2008

 

April 4, 2009

 

year

 

change

 

exchange

 

of currency

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

North America:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

United States

 

$

38,550

 

38.0

%

$

36,489

 

37.5

%

$

(2,061

)

(5.3

)%

N/A

 

(5.3

)%

Canada

 

18,583

 

18.3

%

14,936

 

15.4

%

(3,647

)

(19.6

)%

(3,575

)

(0.4

)%

Mexico

 

5,142

 

5.0

%

4,470

 

4.6

%

(672

)

(13.1

)%

(1,463

)

15.4

%

North America Total

 

62,275

 

61.3

%

55,895

 

57.5

%

(6,380

)

(10.2

)%

(5,038

)

(2.2

)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Asia Pacific:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Southeast Asia/Pacific

 

21,545

 

21.2

%

19,938

 

20.5

%

(1,607

)

(7.5

)%

(4,691

)

14.3

%

East Asia

 

13,615

 

13.4

%

16,955

 

17.4

%

3,340

 

24.5

%

(326

)

26.9

%

North Asia

 

4,135

 

4.1

%

4,511

 

4.6

%

376

 

9.1

%

(393

)

18.6

%

Asia Pacific Total

 

39,295

 

38.7

%

41,404

 

42.5

%

2,109

 

5.4

%

(5,410

)

19.1

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

101,570

 

100.0

%

$

97,299

 

100.0

%

$

(4,271

)

(4.2

)%

$

(10,448

)

6.1

%

 

The decrease in net sales in North America was primarily due to the impact of negative currency exchange rates on net sales in Canada and Mexico and to a decrease in net sales in the United States.  The negative changes to currency decreased net sales in these two markets by $5.0 million year-over-year in the first quarter of 2009.  In local currency, sales in Mexico increased by 15.4% and sales in Canada decreased by 0.4%, compared with the first quarter of last year.  We believe that sales in the United States have been significantly affected by the uncertain economic conditions.

 

The increase in net sales in Asia Pacific came mostly from Hong Kong.  Net sales in that market increased $3.5 million, or 42.0% from the first quarter of 2008, due to an increase in unit sales as a result of significant growth in the number of active Associates.  Additionally, the commencement of operations in the Philippines in January added $1.7 million to net sales.  The increases in these two markets were offset partially by lower sales in Southeast Asia/Pacific.  This was due to negative changes in currency exchange rates, which reduced net sales by $4.7 million.  Overall, changes in currency exchange rates reduced net sales by $5.4 million in our Asia Pacific region.  Each of the markets in our Asia Pacific region, except Singapore and New Zealand, achieved local currency growth on a year-over-year basis.

 

21



Table of Contents

 

Gross Profit

 

Gross profit increased to 79.6% of net sales for the quarter ended April 4, 2009, compared with 78.8% for the same quarter in 2008.  This increase in gross profit margin can be attributed primarily to lower relative freight costs on shipments to customers.  This was partially offset by negative changes in currency exchange rates and moderate increases in costs on certain raw materials.

 

Associate Incentives

 

As a percentage of net sales, Associate incentives increased to 43.1% during the first quarter of 2009, compared with 40.7% for the first quarter of 2008.  This increase was due to the Compensation Plan enhancements that were implemented in the third quarter of 2008, and was partially offset by a decline in base commissions due to changes in currency.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses decreased to 26.0% of net sales for the quarter ended April 4, 2009, compared with 26.6% for the comparable quarter in 2008.  In absolute terms, our selling, general, and administrative expenses decreased by $1.7 million.  The most significant components of this decrease in absolute terms were as follows:

 

·                  A decrease in legal and other professional fees of approximately $1.0 million;

 

·                  A decrease in event production costs of approximately $0.8 million associated with the Asia Pacific Convention, which was not held in 2009 as we hold this event every other year;

 

·                  A decrease in rent expense of approximately $0.4 million; and

 

·                  A decrease in expenses related to advertising and promotional activities of approximately $0.4 million;

 

The decreases in selling, general and administrative expenses listed above were partially offset by an increase in equity-based compensation expense of approximately $1.0 million.

 

The decrease in selling, general and administrative expense as a percentage of net sales can be attributed to the decreases listed above, partially offset by a decrease in net sales.

 

Income Taxes

 

            Income taxes totaled 34.5% of earnings before income taxes for the first quarter of 2009, compared with 37.1% for the first quarter in 2008.  This change was primarily due to increased tax benefits relating to our qualified production activities deduction.

 

Diluted Earnings Per Share

 

Diluted earnings per share decreased $0.01, or 2.3%, to $0.43 in the first quarter of 2009 compared with the first quarter of 2008.  This change was due to a decrease in net sales, offset by lower overall operating costs, a lower effective tax rate, and a lower number of average shares outstanding.

 

Liquidity and Capital Resources

 

We have historically met our working capital and capital expenditure requirements by using both net cash flow from operations and by drawing on our line of credit.  Our principal source of liquidity is our operating cash flow, the availability of which is directly affected by variations in the total revenues of the Company.  There are no material restrictions on our ability to transfer and remit funds among our international markets.

 

22



Table of Contents

 

As disclosed in our 2008 annual report on Form 10-K, we expected to have unusual cash payments during the first half of 2009.  During the first quarter of 2009 we paid $7.0 million for an arbitration award and $1.3 million in tax payments resulting from an IRS audit.  Additionally, we experienced a decrease in net earnings, as well as an increase in inventories due to increased safety stock levels in many of our markets, lower than expected sales in the United States, and higher inventory values resulting from changes in currency exchange rates.  As a result of these items, we had a net use of cash for operating activities of $1.3 million.

 

As a U.S.-based, multi-national company, reporting in U.S. dollars, we have received a benefit to net sales for the last several years from changes in currency exchange rates as the U.S. dollar was relatively weak.  Net sales and earnings during the first quarter of 2009, however, were negatively affected by a significant strengthening of the U.S. dollar.  In general, our reported sales and earnings are affected positively by a weakening of the U.S. dollar and negatively by a strengthening of the U.S. dollar.  Although it is difficult to estimate the impact that changes in currency exchange rates may have on our future operating results, we believe changes in currency exchange rates will have a significant negative effect on net sales and cash flows from operating activities in 2009.

 

Cash and cash equivalents decreased to $9.7 million at April 4, 2009, from $13.3 million at January 3, 2009.  Net working capital increased to $5.8 million at April 4, 2009 from ($1.9) million at January 3, 2009.  This increase in net working capital was due mostly to a decrease in other current liabilities as a result of the arbitration and tax payments mentioned above.  The impact of these payments on our cash balance was partially offset by decreased spending on property, plant, and equipment due to the completion of the facility expansion projects that had been in progress for the last couple of years.

 

We have a share repurchase plan that has been ongoing since the fourth quarter of 2000.  Our Board of Directors periodically approves additional dollar amounts for share repurchase under that plan.  Share repurchases are made from time-to-time, in the open market, through block trades or otherwise, and are based on market conditions, the level of cash balances, general business opportunities, and other factors.  There were no share repurchases during the first quarter of 2009.  There currently is no expiration date on the remaining approved repurchase amount of $10.4 million and no requirement for future share repurchases.

 

We currently maintain a $40.0 million credit facility with Bank of America.  As of April 4, 2009, our balance on this line of credit was $33.9 million.  We will be required to pay the balance on this line of credit in full at the time of maturity in May 2011.  This credit agreement contains restrictive covenants, which require us to maintain a consolidated rolling four-quarter EBITDA equal to or greater than $50.0 million, and a ratio of consolidated funded debt to EBITDA of 2.5 to 1.0 at the end of each quarter.  As of April 4, 2009, we were in compliance with these covenants.  Management is not aware of any issues currently impacting Bank of America’s ability to honor their commitment to extend credit under this facility.

 

We believe that current cash balances, future cash provided by operations, and amounts available under our line of credit will be sufficient to cover our operating and capital needs in the ordinary course of business for the foreseeable future.  Additionally, to accommodate the unusual cash needs of 2009, we may delay capital projects and reduce or eliminate the amount of share repurchases in 2009.  If we experience an adverse operating environment or unusual capital expenditure requirements, additional financing may be required.  No assurance can be given, however, that additional financing, if required, would be available or on favorable terms.  We might also require or seek additional financing for the purpose of expanding new markets, growing our existing markets, or for other reasons.  Such financing may include the use of additional debt or the sale of additional equity securities.  Any financing which involves the sale of equity securities or instruments that are convertible into equity securities could result in immediate and possibly significant dilution to our existing shareholders.

 

Item 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Our earnings, cash flows, and financial position are affected by fluctuations in currency exchange rates, interest rates, and other uncertainties that are inherent in doing business and selling product in more than one currency.  In addition, our operations are exposed to risks that are associated with changes in social, political, and economic conditions in our international operations.  This includes changes in the laws and policies that govern investment in international countries where we have operations, as well as, to a lesser extent, to changes in United States laws and regulations relating to international trade and investment.

 

23



Table of Contents

 

Foreign Currency Risks.  Net sales outside the United States represented 62.0% and 62.5% of our net sales in the quarters ended March 29, 2008 and April 4, 2009, respectively.  Because a significant portion of our sales are generated outside the United States, currency exchange rate fluctuations may have a significant effect on our sales and earnings.  This risk is partially mitigated by the fact that our sales are spread across 14 countries, with Canada being our largest international market, at 15.4% of net sales in the first quarter of 2009, followed by Hong Kong and Australia at 12.2% and 7.7%, respectively.  The local currency of each international subsidiary is considered the functional currency, with all revenue and expenses being translated at weighted-average currency exchange rates for the applicable periods.  In general, our reported sales and earnings are affected positively by a weakening of the U.S. dollar and negatively by a strengthening of the U.S. dollar.  Changes in currency exchange rates may also affect our product margins, because we manufacture the majority of our products in the U.S. and sell them to our international subsidiaries in their respective functional currencies.  We are unable to reasonably estimate the effect that currency fluctuations may have on our future business, results of operations, or financial condition.  This is due to the uncertainty in, and the varying degrees and type of exposure that we face from, fluctuations in various currencies.

 

We seek to reduce exposure to fluctuations in currency exchange rates by creating offsetting positions through the use of currency exchange contracts on cash that we repatriate.  We do not use derivative financial instruments for trading or speculative purposes.  Our use of currency exchange contracts includes the purchase of put and call options, which give us the right, but not the obligations, to sell or buy international currency at a specified exchange rate (“strike price”).  In addition, we have used forward contracts to supplement our use of options.  These contracts provide protection in the event that the currency weakens beyond the option strike price.  The fair value of these contracts is estimated based on period-end quoted market prices, and the resulting asset and expense, which historically has not been material, is recognized in our Consolidated Financial Statements.  There can be no assurance that our practices will be successful in eliminating all or substantially all of the risks that may be encountered in connection with our currency transactions.  As of April 4, 2009, we had no currency exchange contracts in place.

 

Following are the average exchange rates of currency units to one U.S. dollar for each of our international markets for the periods indicated:

 

 

 

Quarter Ended

 

 

 

March 29,

 

April 4,

 

 

 

2008

 

2009

 

 

 

 

 

 

 

Canadian Dollar

 

1.00

 

1.24

 

Australian Dollar

 

1.11

 

1.50

 

New Zealand Dollar

 

1.27

 

1.87

 

Hong Kong Dollar

 

7.79

 

7.75

 

Japanese Yen

 

105.39

 

93.83

 

New Taiwan Dollar

 

31.56

 

33.98

 

Korean Won

 

954.48

 

1,411.30

 

Singapore Dollar

 

1.41

 

1.51

 

Mexican Peso

 

10.81

 

14.35

 

Chinese Yuan

 

7.17

 

6.84

 

Malaysian Ringitt

 

3.23

 

3.63

 

Philippine Peso

 

*

 

47.68

 

 


* USANA operations had not commenced during period indicated.

 

Interest Rate Risks.  As of April 4, 2009, we had a balance of $33.9 million outstanding on our line of credit, with a weighted-average interest rate of 1.56%.  This interest rate is computed at the bank’s Prime Rate, or LIBOR, adjusted by features specified in our loan agreements, with fixed rate term options of up to six months.  The annual impact on after-tax expense of a 100-basis-point increase in the interest rate on the above balance would not materially affect our earnings.  If, however, we are unable to meet the covenants in our loan agreement, we would be required to renegotiate the terms of credit under the loan agreement, including the interest rate.  There can be no assurance that any renegotiated terms of credit would not materially impact our earnings.

 

24



Table of Contents

 

Item 4.    CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information that is required to be disclosed in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods that are specified in the SEC’s rules and forms and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding any required disclosure.  In designing and evaluating these disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

 

As of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a- 15(e) under the Exchange Act).  Based on this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of April 4, 2009.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting that occurred during the quarter ended April 4, 2009 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

25



Table of Contents

 

PART II.   OTHER INFORMATION

 

Item 6.    EXHIBITS

 

Exhibit

 

 

Number

 

Description

 

 

 

3.1

 

Amended and Restated Articles of Incorporation (Incorporated by reference to Report on Form 8-K, filed April 25, 2006)

 

 

 

3.2

 

Bylaws (Incorporated by reference to Report on Form 8-K, filed April 25, 2006)

 

 

 

4.1

 

Specimen Stock Certificate for Common Stock, no par value (Incorporated by reference to Registration Statement on Form 10, File No. 0-21116, effective April 16, 1993)

 

 

 

10.1

 

2002 USANA Health Sciences, Inc. Stock Option Plan (Incorporated by reference to Registration Statement on Form S-8, filed July 18, 2002)*

 

 

 

10.2

 

Form of employee or director non-statutory stock option agreement under the 2002 Stock Option Plan (Incorporated by reference to Report on Form 10-K, filed March 6, 2006)*

 

 

 

10.3

 

Form of employee incentive stock option agreement under the 2002 Stock Option Plan (Incorporated by reference to Report on Form 10-K, filed March 6, 2006)*

 

 

 

10.4

 

Credit Agreement by and between Bank of America, N.A. and USANA Health Sciences, Inc. (Incorporated by reference to Report on Form 10-Q for the period ended July 3, 2004)

 

 

 

10.5

 

Amendment dated May 17, 2006 to Credit Agreement dated June 16, 2004 (Incorporated by reference to Report on Form 10-Q for the period ended September 30, 2006)

 

 

 

10.6

 

Amendment dated April 24, 2007 to Credit Agreement dated June 16, 2004 (Incorporated by reference to Report on Form 10-Q for the period ended March 31, 2007)

 

 

 

10.7

 

USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 25, 2006)*

 

 

 

10.8

 

Form of Stock Option Agreement for award of non-statutory stock options to employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*

 

 

 

10.9

 

Form of Stock Option Agreement for award of non-statutory stock options to directors who are not employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*

 

 

 

10.10

 

Form of Incentive Stock Option Agreement under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*

 

 

 

10.11

 

Form of Stock-Settled Stock Appreciation Rights Award Agreement for employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*

 

 

 

10.12

 

Form of Stock-Settled Stock Appreciation Rights Award Agreement for directors who are not employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*

 

 

 

10.13

 

Form of Deferred Stock Unit Award Agreement for grants of deferred stock units to directors who are not employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*

 

26



Table of Contents

 

10.14

 

Form of Indemnification Agreement between the Company and its directors (Incorporated by reference to Report on Form 8-K, filed May 24, 2006)*

 

 

 

10.15

 

Form of Indemnification Agreement between the Company and certain of its officers (Incorporated by reference to Report on Form 8-K, filed May 24, 2006)*

 

 

 

11.1

 

Computation of Net Income per Share (included in Notes to Consolidated Financial Statements)

 

 

 

31.1

 

Certification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

31.2

 

Certification of Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

32.1

 

Certification of Chief Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350

 

 

 

32.2

 

Certification of Chief Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350

 


* Denotes a management contract or compensatory plan or arrangement.

 

27



Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

USANA HEALTH SCIENCES, INC.

 

 

Date:

May 12, 2009

 

/s/ Jeffrey A. Yates

 

 

 

Jeffrey A. Yates

 

 

 

Chief Financial Officer
(Principal Financial and Accounting Officer)

 

28